Venus Remedies Limited — Board Meeting, 26-05-2025: Outcome of Board Meeting

Venus Remedies reported a strong FY25 with consolidated revenue rising to Rs. 847.89 Cr from Rs. 601.45 Cr and profit after exceptional items jumping to Rs. 71.83 Cr versus Rs. 44.64 Cr last year. EPS stood at Rs. 21.31. The board approved re-appointment of key directors including the MD for five years, pending shareholder nod. New secretarial, cost, and internal auditors were appointed. The company also wrote off Rs. 38.68 Cr of time-barred FCCB liability, booking the related accrued interest as an exceptional expense.